Table 2 Relative abundance of individual metabolites in serum.

From: Targeted metabolomics analysis of serum and Mycobacterium tuberculosis antigen-stimulated blood cultures of pediatric patients with active and latent tuberculosis

Metabolite

Relative abundance

p value

Adjusted p value

HC vs. TB

HC vs, LTBI

HC vs. NMP

Leucine (Leu)

2.157

1.251

− 2.807

0.001

0.015

Citrulline (Cit)

− 1.020

− 1.014

2.199

0.001

0.015

Glycyl-L-valine

0.494

0.053

− 0.669

0.024

0.243

Tyrosine (Tyr)

0.645

− 0.930

2.273

0.052

0.393

Neopterin (Neo)

− 0.598

− 0.226

− 4.026

0.079

0.436

Asparagine (Asn)

− 0.429

0.121

2.021

0.087

0.436

Pyroglutamic acid (Glp)

− 2.038

3.654

− 3.595

0.177

0.735

Phenyloalanine (Phe)

6.552

2.150

− 3.551

0.264

0.735

Alanine (Ala)

− 1.575

4.754

− 6.130

0.271

0.735

Glutathione (GSH)

23.781

12.918

37.071

0.301

0.735

Cysteine (Cys)

− 13.784

− 11.677

0.452

0.324

0.735

Inosine (Ino)

− 1.332

− 0.307

0.939

0.359

0.735

Glycine (Gly)

2.657

2.871

− 1.251

0.401

0.735

Tryptophan (Trp)

− 2.401

− 2.828

− 3.055

0.418

0.735

Isoleucine (Ile)

0.977

0.050

− 0.929

0.429

0.735

Hydroxyproline (Hyp)

− 0.268

− 0.236

− 1.203

0.459

0.735

Cystine

0.019

0.007

− 0.004

0.479

0.735

Proline (Pro)

− 2.383

− 0.903

3.031

0.479

0.735

Threonine (Thr)

− 12.344

− 5.636

− 20.555

0.494

0.735

Methionine (Met)

0.257

0.440

− 0.173

0.501

0.735

Serine (Ser)

1.052

1.111

− 0.755

0.514

0.735

Lysine (Lys)

1.024

− 0.744

− 0.542

0.543

0.741

Para-aminobenzoic acid (PABA)

− 0.629

− 2.477

0.632

0.582

0.747

Kynurenine (Kyn)

0.647

− 0.229

− 0.801

0.609

0.747

Gamma-aminobutyric acid (GABA)

0.180

0.043

− 0.199

0.623

0.747

Glutamine (Gln)

0.370

− 1.228

4.076

0.710

0.819

Valine (Val)

− 1.511

− 0.782

− 2.196

0.782

0.868

Arginine (Arg)

− 0.426

− 0.101

− 0.041

0.866

0.928

Pyridoxal

0.00008

− 0.001

− 0.003

0.985

0.985

Isopyridoxal

0.009

− 0.001

− 0.003

0.985

0.985

  1. HC M.tb-uninfected healthy controls, LTBI latently M.tb-infected individuals, NMP patients with nonmycobacterial pneumonia, TB active tuberculosis patients.
Back to article page